Stockscreener 앱 받기
22.55
2.59%
-0.60
시간 외 거래:
22.11
-0.44
-1.95%
전일 마감가:
$23.15
열려 있는:
$22.72
하루 거래량:
1.22M
Relative Volume:
1.20
시가총액:
$1.84B
수익:
$305.00K
순이익/손실:
$-328.98M
주가수익비율:
-5.287
EPS:
-4.2652
순현금흐름:
$-309.60M
1주 성능:
-2.68%
1개월 성능:
+4.16%
6개월 성능:
+65.57%
1년 성능:
-1.27%
1일 변동 폭
$22.14
$23.05
1주일 범위
$22.14
$24.23
52주 변동 폭
$9.90
$27.20
Viridian Therapeutics Inc Stock (VRDN) Company Profile
명칭
Viridian Therapeutics Inc
전화
617.272.4600
주소
221 CRESCENT STREET, WALTHAM
VRDN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VRDN
Viridian Therapeutics Inc
|
22.55 | 2.16B | 305.00K | -328.98M | -309.60M | -4.2652 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.67 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
628.00 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
423.47 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
831.48 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.77 | 39.72B | 447.02M | -1.18B | -906.14M | -6.1812 |
Viridian Therapeutics Inc Stock (VRDN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-25 | 재개 | Jefferies | Buy |
| 2024-12-19 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-11-25 | 개시 | TD Cowen | Buy |
| 2024-09-11 | 재확인 | Needham | Buy |
| 2024-06-11 | 개시 | Wolfe Research | Outperform |
| 2024-06-06 | 개시 | Goldman | Buy |
| 2024-05-09 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2024-05-09 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2023-06-14 | 개시 | BTIG Research | Buy |
| 2023-06-14 | 재개 | Credit Suisse | Outperform |
| 2023-05-30 | 개시 | RBC Capital Mkts | Outperform |
| 2023-04-17 | 개시 | Wells Fargo | Overweight |
| 2023-03-30 | 개시 | Stifel | Buy |
| 2022-12-19 | 개시 | Cowen | Outperform |
| 2022-12-19 | 개시 | Needham | Buy |
| 2022-12-16 | 개시 | Credit Suisse | Outperform |
| 2022-12-01 | 개시 | H.C. Wainwright | Buy |
| 2022-06-23 | 개시 | B. Riley Securities | Buy |
| 2021-11-18 | 개시 | SVB Leerink | Outperform |
| 2021-10-12 | 개시 | Evercore ISI | Outperform |
| 2021-01-25 | 개시 | Ladenburg Thalmann | Buy |
모두보기
Viridian Therapeutics Inc 주식(VRDN)의 최신 뉴스
Viridian Therapeutics, Inc. (VRDN) May Report Negative Earnings: Know the Trend Ahead of Q3 Release - Yahoo Finance
Viridian submits BLA for veligrotug to treat TED - Eyes On Eyecare
Corton Capital Inc. Makes New Investment in Viridian Therapeutics, Inc. $VRDN - MarketBeat
VRDN: BTIG Reiterates 'Buy' Rating and Price Target at $61.00 | - GuruFocus
Chart based analysis of Viridian Therapeutics Inc. trendsQuarterly Trade Review & Consistent Income Trade Ideas - newser.com
How buybacks impact Viridian Therapeutics Inc. stock value2025 Analyst Calls & Verified Entry Point Detection - newser.com
Is Viridian Therapeutics Inc. stock a smart buy before Fed meeting2025 Year in Review & Fast Gain Stock Trading Tips - newser.com
Smart tools for monitoring Viridian Therapeutics Inc.’s price action2025 Geopolitical Influence & Real-Time Chart Pattern Alerts - newser.com
Viridian Therapeutics submits Biologics License Application to FDA for veligrotug - Ophthalmology Times
Viridian Therapeutics submits BLA for thyroid disease drug - Traders Union
Viridian Therapeutics (VRDN) Submits BLA for Veligrotug to FDA - GuruFocus
Trend analysis for Viridian Therapeutics Inc. this weekWeekly Risk Report & AI Forecast for Swing Trade Picks - newser.com
Can Viridian Therapeutics Inc. stock attract ESG capital inflowsJuly 2025 Pullbacks & Daily Stock Momentum Reports - newser.com
Viridian Therapeutics Announces Successful October Submission of Biologics License Application (BLA) to U.S. FDA for Veligrotug in Thyroid Eye Disease - The Joplin Globe
How hedge fund analytics apply to Viridian Therapeutics Inc. stockTrade Ideas & Weekly High Momentum Picks - newser.com
How Viridian Therapeutics Inc. stock reacts to job market dataQuarterly Portfolio Summary & Target Return Focused Picks - newser.com
Can machine learning forecast Viridian Therapeutics Inc. recovery2025 Top Gainers & Weekly High Return Stock Forecasts - newser.com
Can swing trading help recover from Viridian Therapeutics Inc. lossesShare Buyback & Community Consensus Trade Alerts - newser.com
Top chart patterns to watch in Viridian Therapeutics Inc.Rate Cut & High Win Rate Trade Tips - newser.com
Will Viridian Therapeutics Inc. (1S1) stock attract long term capital inflows2025 Key Lessons & Fast Exit and Entry Trade Guides - newser.com
Chart based exit strategy for Viridian Therapeutics Inc.2025 Price Momentum & Weekly High Return Stock Forecasts - newser.com
Why Viridian Therapeutics Inc. (1S1) stock is a must watch tickerWeekly Stock Analysis & Verified Chart Pattern Signals - newser.com
Regression analysis insights on Viridian Therapeutics Inc. performanceDay Trade & Free Verified High Yield Trade Plans - newser.com
Is Viridian Therapeutics Inc. stock attractive for growth ETFsSell Signal & Community Consensus Trade Alerts - newser.com
Oppenheimer Maintains Viridian Therapeutics (VRDN) Outperform Recommendation - MSN
Moody Aldrich Partners LLC Has $1.25 Million Stake in Viridian Therapeutics, Inc. $VRDN - MarketBeat
Reassessing Viridian Therapeutics (VRDN) Valuation Following Insider Buying and Progress in Thyroid Eye Disease Program - Sahm
Astria, Viridian Therapeutics, and More Stocks See Action From Activist Investors - Barron's
Fairmount Funds Management LLC's Strategic Acquisition in Viridi - GuruFocus
Wedbush Reduces Earnings Estimates for Viridian Therapeutics - MarketBeat
How supply chain issues affect Viridian Therapeutics Inc. stock2025 Top Decliners & Free High Return Stock Watch Alerts - newser.com
How Viridian Therapeutics Inc. stock performs in interest rate cyclesEarnings Miss & Consistent Growth Stock Picks - newser.com
Is Viridian Therapeutics Inc. (1S1) stock a buy on weaknessTrade Volume Report & Real-Time Volume Surge Alerts - newser.com
Using Ichimoku Cloud for Viridian Therapeutics Inc. technicalsEarnings Overview Report & Short-Term High Return Ideas - newser.com
Viridian Therapeutics Inc (VRDN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.45%
0.86%
자본화:
|
볼륨(24시간):